Term ends Jun 6, 2028 · Medium confidence
20-year base term ends Jun 6, 2028
Why Medium: A parent in the chain could not be resolved.
Held by Aptalis Pharma Canada ULC
Filed Oct 3, 2008 as application 12/245,648 · Granted Jun 2, 2009
Base term, 20 years from filing
Today
2008
2028
Clock starts
Jun 6, 2008
Jun 6, 2008
Term ends
Jun 6, 2028
Jun 6, 2028
Granted
Jun 2, 2009
Jun 2, 2009
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
28
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 6, 2008, when application 12/135,103, the earliest non-provisional in its chain, was filed (this one was filed Oct 3, 2008); a parent in its chain could not be resolved (the next row) | Jun 6, 2028 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 6, 2028 | Medium confidence |
This family
| US 8,604,222 | Lapsed on the fee record Dec 2025 | Dec 2025 |
| US 8,246,950 | In force Feb 2028 | Feb 2028 |
| US 8,221,747 | In force Feb 2028 | Feb 2028 |
| US 8,293,229 | In force Mar 2031 | Mar 2031 |
| US 7,541,384 | this patent Jun 2028 | Jun 2028 |
| US 10,087,493 | In force Mar 2029 | Mar 2029 |
| US 8,217,083 | In force Jun 2028 | Jun 2028 |
| US 8,784,884 | In force Aug 2031 | Aug 2031 |
8 of 28 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 13, 2011 Reel 27373, frame 622 | Axcan Pharma Inc. | Axcan Pharma Canada Inc. | Change of Name |
| Dec 16, 2011 Reel 27401, frame 722 | Axcan Pharma Inc. | Aptalis Pharma Canada Inc. | Change of Name |
| Oct 31, 2013 Reel 31531, frame 488 | Aptalis Pharma Canada Inc.; Aptalis Pharma US, Inc.; Aptalis Pharmatech, Inc. | Bank of America, N.A., as Administrative Agent | Patent Security Agreement |
| Jan 31, 2014 Reel 32149, frame 111 | Bank of America, N.A., as Administrative Agent | Aptalis Pharma US, Inc.; Aptalis Pharmatech, Inc.; Aptalis Pharma Canada Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharma US, Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharmatech, Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharma Canada Inc. | Termination and Release |
| Mar 18, 2016 Reel 38037, frame 424 | Aptalis Pharma Canada Inc. | Aptalis Pharma Canada ULC | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jun 2028
Term ends Jun 6, 2028. No further fees fall due before then
Citations
3
later US patents cite this one
That is below the median of utility patents granted in 2009 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.